



Engineered TCR and CAR Cells for Immunotherapy of Solid Tumors

Guest Editors:

Dr. Michael Morgan

Institute of Experimental
Hematology, Hannover Medical
School, 30625 Hannover,
Germany

Dr. Vinagolu K. Rajasekhar

Memorial Sloan-Kettering Cancer
Center, New York, NY, USA

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

The Special Issue of Biomolecules is titled “Engineered TCR and CAR Cells for Immunotherapy of Solid Tumors”. Use of adoptive cell therapy strategies to treat cancer, including solid tumors, continues to be a rapidly evolving therapeutic paradigm. The successful clinical application of engineered T cell receptor (TCR) or chimeric antigen receptor (CAR) T cells to treat B cell malignancies, such as leukemia, lymphoma and multiple myeloma, has quickly transformed modern medicine. These concepts have been expanded to include additional immune cell sources, such as natural killer (NK) cells, dendritic cells (DC) and macrophages.

This Special Issue will highlight current and emerging concepts and strategies to target and eliminate solid tumors using engineered immune cells, including recent progress in preclinical and clinical studies that may direct development of more efficacious therapeutic strategies. The journal Biomolecules encourages clinicians and researchers to submit their original research or reviews on use of modified immune cells to treat solid tumors for consideration of publication in this Special Issue.

Guest Editors





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
X@Biomol_MDPI